Revuforj (revumenib tablets – Syndax) — Cigna

Initial criteria

• Patient is age ≥ 1 year
• Patient has relapsed disease OR patient has refractory disease
• Disease is positive for a lysine methyltransferase 2A (KMT2A) gene translocation

Approval duration

1 year